Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
AssigneeThe Scripps Research Institute
InventorFrancis V. Chisari
Life of this patent
Estimating the term…
Abstract
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV polymerase, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
Claims16
A CTL inducing peptide comprising from eight to thirteen amino acids, wherein at least a majority of the amino acids are homologous to a corresponding portion of HBpol having the sequence:
- 7 HBpol4-13 [Seq ID No. 12] Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu;
- HBpol108-116 [Seq ID No. 13] Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg;
- HBpol139-147 [Seq ID No. 14] Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol151-160 [Seq ID No. 15] His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol152-161 [Seq ID No. 16] Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 [Seq ID No. 2] Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu;
- HBpol505-514 [Seq ID No. 17] Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe;
- HBpol551-559 [Seq ID No. 18] Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala;
- HBpol575-583 [Seq ID No. 19] Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu;
- HBpol655-663 [Seq ID No. 20] Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile;
- HBpol748-757 [Seq ID No. 21] Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg;
- HBpol758-766 [Seq ID No. 22] Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu);
- HBpol773-782 [Seq ID No. 3] Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val or HBpol816-824 [Seq ID No. 5] Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu
A method for stimulating a cytotoxic T lymphocyte response to hepatitis B virus which comprises exposing cytotoxic T lymphocytes of a host to a peptide which contains a CTL epitope and which comprises from eight to thirteen amino acids, wherein at least a majority of the amino acids are homologous to a corresponding portion of HBpol having the sequence:
- 9 HBpol14-13 [Seq ID No. 12] Ser-Tyr-Gln-His-Phe-Arg-Lys-Leu-Leu-Leu;
- HBpol108-116 [Seq ID No. 13] Arg-Leu-Lys-Leu-Ile-Met-Pro-Ala-Arg;
- HBpol139-147 [Seq ID No. 14] Val-Val-Asn-His-Tyr-Phe-Gln-Thr-Arg HBpol151-160 [Seq ID No. 15] His-Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr HBpol152-161 [Seq ID No. 16] Thr-Leu-Trp-Lys-Ala-Gly-Ile-Leu-Tyr-Lys HBpol 455-463 [Seq ID No. 23] Gly-Leu-Ser-Arg-Tyr-Val-Ala-Arg-Leu;
- HBpol505-514 [Seq ID No. 17] Leu-Tyr-Ser-His-Pro-Ile-Ile-Leu-Gly-Phe;
- HBpol551-559 [Seq ID No. 18] Tyr-Met-Asp-Asp-Val-Val-Leu-Gly-Ala;
- HBpol575-583 [Seq ID No. 19] Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu;
- HBpol655-663 [Seq ID No. 20] Ala-Leu-Met-Pro-Leu-Tyr-Ala-Cys-Ile HBpol748-757 [Seq ID No. 21] Gly-Thr-Asp-Asn-Ser-Val-Val-Leu-Ser-Arg HBpol758-766 [Seq ID No. 22] Lys-Tyr-Thr-Ser-Phe-Pro-Trp-Leu-Leu) HBpol773-782 [Seq ID No. 3] Ile-Leu-Arg-Gly-Thr-Ser-Phe-Val-Tyr-Val or HBpol816-824 [Seq ID No. 5] Phe-Leu-Leu-Ser-Leu-Gly-Ile-His-Leu
Dependencies are inferred from the claim text.